Abiopharma

NRx Pharmaceuticals Inc (NRXP) Announces Clinical Trial Update NRx Pharmaceuticals Inc (NRXP) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: Company
• Diseases/Conditions: success
• Collaboration: National Science Board Presidential Appointee
• Updated Timeline: 2018-2024
  • targeting the NMDA-receptor in the brain, which represents potentially a key new mechanism to treat depression with and without suicidality, PTSD and other indications. To date, NRX-101 is the only oral NMDA investigational medicine focused on bipolar depression in patients with acute and sub-acute suicidality. In the coming year, the Company aims to complete the FDA registration trials for NRX-101 under a Special Protocol Agreement (SPA) awarded by the FDA. 2 About NRx Pharmaceuticals NRx Pharmaceuticals, Inc. draws upon decades of collective, scientific, and drug-development experience applying innovative science to known molecules to address very high unmet needs and bring improved health to patients. NRx Pharmaceuticals is led by executives who have held leadership roles at Lilly, Pfizer, and Novartis as well as major investment banking institutions. Cautionary Note Regarding Forward-Looking Statements This announcement of NRx Pharmaceuticals, Inc. includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995